Alexandre Andre Balieiro Anstacio Da Costa, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystadenocarcinoma, Serous | 5 | 2017 | 450 | 1.100 |
Why?
|
| Endometrial Neoplasms | 7 | 2020 | 1351 | 0.980 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 4839 | 0.910 |
Why?
|
| Neoplasm, Residual | 4 | 2022 | 973 | 0.820 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 221 | 0.820 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 1142 | 0.750 |
Why?
|
| Platinum Compounds | 1 | 2019 | 96 | 0.660 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2019 | 98 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 5172 | 0.650 |
Why?
|
| Cyclin E | 1 | 2019 | 172 | 0.650 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 108 | 0.580 |
Why?
|
| Lymph Node Excision | 5 | 2022 | 1262 | 0.580 |
Why?
|
| Lymphatic Metastasis | 7 | 2022 | 2924 | 0.560 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2021 | 710 | 0.540 |
Why?
|
| Oncogene Proteins | 1 | 2019 | 749 | 0.500 |
Why?
|
| Hysterectomy | 4 | 2021 | 927 | 0.490 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2014 | 25 | 0.490 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 794 | 0.470 |
Why?
|
| Platinum | 1 | 2015 | 233 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11525 | 0.430 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1149 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 9240 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1862 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 3616 | 0.340 |
Why?
|
| Mouth Neoplasms | 1 | 2014 | 601 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2022 | 2020 | 0.310 |
Why?
|
| Carcinoma | 1 | 2019 | 2375 | 0.290 |
Why?
|
| Brazil | 3 | 2019 | 1270 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4034 | 0.280 |
Why?
|
| Neoplasm Staging | 11 | 2022 | 11031 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 705 | 0.230 |
Why?
|
| Conization | 1 | 2021 | 14 | 0.200 |
Why?
|
| Lymphocele | 1 | 2020 | 16 | 0.190 |
Why?
|
| Prognosis | 7 | 2022 | 29060 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2018 | 53 | 0.170 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 272 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 271 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 2727 | 0.160 |
Why?
|
| Survival Rate | 4 | 2016 | 12788 | 0.150 |
Why?
|
| Retreatment | 1 | 2019 | 610 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77460 | 0.140 |
Why?
|
| Myometrium | 1 | 2017 | 181 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2017 | 23336 | 0.130 |
Why?
|
| Middle Aged | 13 | 2021 | 213390 | 0.130 |
Why?
|
| Ovary | 1 | 2020 | 981 | 0.130 |
Why?
|
| Aged | 11 | 2021 | 163288 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8642 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2015 | 507 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 57776 | 0.120 |
Why?
|
| Female | 19 | 2023 | 380193 | 0.110 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2017 | 337 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 39052 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 12356 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3476 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 403 | 0.100 |
Why?
|
| Heterozygote | 1 | 2019 | 2804 | 0.100 |
Why?
|
| Adult | 11 | 2021 | 214052 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3480 | 0.100 |
Why?
|
| Carboplatin | 1 | 2014 | 801 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1788 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1941 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 4185 | 0.090 |
Why?
|
| Fluorouracil | 1 | 2014 | 1619 | 0.090 |
Why?
|
| Cisplatin | 1 | 2014 | 1662 | 0.080 |
Why?
|
| Humans | 19 | 2023 | 744366 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6539 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2019 | 10252 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2019 | 3444 | 0.070 |
Why?
|
| Patient Selection | 1 | 2017 | 4216 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6896 | 0.060 |
Why?
|
| Receptor, erbB-3 | 1 | 2021 | 142 | 0.050 |
Why?
|
| Risk Factors | 2 | 2017 | 72296 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 11366 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 41005 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 425 | 0.030 |
Why?
|
| Male | 3 | 2018 | 350115 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 2016 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2645 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2417 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20824 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9145 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 6234 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 56429 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 29144 | 0.010 |
Why?
|